Abstract: Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.

Abstract: Aspects of the disclosure concern methods and compositions related to recombinant microorganisms expressing one or more biologically active peptides that are heterologous to the microorganism, wherein the one or more biologically active peptides comprise a potassium channel blocker. In particular aspects, recombinant microorganisms are generated by introducing into the microorganism one or more polynucleotides encoding one or more biologically active peptides. In specific aspects, a subject having one or more diseases or conditions mediated by cells of the immune system and/or fibroblasts or fibroblast-like cells is administered a therapeutically effective amount of a recombinant microorganism or composition thereof, wherein the recombinant microorganism is capable of producing a therapeutically effective amount of the one or more biologically active polypeptides to treat or prevent the one or more diseases or conditions mediated by cells of the immune system and/or fibroblasts or fibroblast-like cells.

Abstract: The present disclosure provides compositions comprising encapsulated engineered bacteria. The bacteria may be engineered to act as sensors of biomarkers, such as inflammation, as well as to produce diagnostic or therapeutic agents.

Abstract: The present invention relates to inhibitors of protein fucosylation. More specifically, the present invention relates to carbacyclic compounds of Formula (I) useful as inhibitors of protein fucosylation, or for treating a cancer, an autoimmune disease, an infectious disease, an inflammatory disease, or sickle cell disease.

Abstract: The present invention relates to methods and intermediates for the synthesis of nucleosides and nucleoside analogues (NAs). More specifically, the present invention relates to methods of synthesizing nucleosides and NAs, using simple achiral materials by a ‘one-pot’ proline-catalyzed halogenation of a heteroaryl-substituted acetaldehyde together with a tandem enantioselective aldol reaction followed by a reduction or organometallic addition and cyclization (annulation) reaction involving halide displacement.

Abstract: The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging:

Abstract: A journal bearing for a crankshaft having indentations on the journal surface is disclosed. The indentations are designed to increase lubricant volume and decrease friction between the journal surface and the bearing surface. The indentations may be designed to intensify the hydrodynamic pressure when the crankshaft is rotating.

Abstract: The present invention provides 18F-labeled amino acids or derivatives thereof having formula (I) and methods of making same, which can be suitable for PET imaging:

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1 and n are as described herein, compositions including the compounds and methods of using the compounds.

Abstract: The present invention discloses that essential and highly conserved GTPases (i.e., for example, YlqF, YqeH, YsxC, or YphC proteins) from Bacillus subtilis participate in ribosome biogenesis. Before this invention, the biological function of the GTPase proteins were unknown. These GTPase proteins are disclosed to affect translation and believed to promote ribosome biogenesis. For example, cells depleted of YlqF protein accumulate a precursor of the 50S subunit that migrates at 45S, suggesting a role in assembly of the large ribosomal subunit. Analysis of the protein content of the 45S particle showed that ribosomal protein L16 is missing from the large subunit. Inhibitors of GTPase-ribosomal interactions (i.e., for example, ribosomal protein or ribosomal nucleic acids) comprise a novel class of antimicrobial compounds.

Abstract: Novel granulatimide compounds and pharmaceutical formulations thereof are provided.